コンテンツへスキップ
Merck
  • Successful medical treatment in a child with E. coli ESBL meningitis with acute communicating hydrocephalus and ventricular empyema: a case report.

Successful medical treatment in a child with E. coli ESBL meningitis with acute communicating hydrocephalus and ventricular empyema: a case report.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet (2013-03-22)
Chanapai Chaiyakulsil, Olarn Prommalikit
要旨

Extended-spectrum beta-lactamase (ESBL) producing organisms cause wide spectrum of diseases including urinary tract infection, cholangitis, intra-abdominal abscess or pneumonia but rarely meningitis. The present report a successful nonsurgical, medical treatment in a child with Escherichia coli ESBL meningitis with acute symptomatic communicating hydrocephalus and ventricular empyema. Incidence of infections from ESBL producing organisms are increasingly emerging and causing wide spectrum of illnesses which prompts for both aggressive medical and surgical intervention to prevent morbidity and mortality. Antimicrobial agents must be vigilantly utilized to prevent possible development of new highly-resistant organisms.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ペニシリナーゼ Bacillus cereus由来, lyophilized powder, 1,500-3,000 units/mg protein (using benzylpenicillin)
Sigma-Aldrich
β-ラクタマーゼ 緑膿菌由来, recombinant, expressed in E. coli
Sigma-Aldrich
β-ラクタマーゼ Enterobacter cloacae由来, Type IV, lyophilized powder, 0.2-0.6 units/mg protein (using benzylpenicillin)
Sigma-Aldrich
ペニシリナーゼ Bacillus cereus由来, lyophilized, powder, white, ~13 U/mg
Sigma-Aldrich
β-ラクタマーゼ 蛍光菌Pseudomonas fluorescens由来, lyophilized powder, recombinant, expressed in E. coli